Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at Alliance Global Partners

Alliance Global Partners began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price objective on the specialty pharmaceutical company’s stock.

Separately, StockNews.com upgraded Lipocine from a hold rating to a buy rating in a research report on Friday, September 20th.

Lipocine Price Performance

LPCN opened at $4.44 on Tuesday. Lipocine has a fifty-two week low of $2.31 and a fifty-two week high of $11.79. The company has a market capitalization of $23.75 million, a P/E ratio of -2.60 and a beta of 1.21. The firm’s fifty day moving average price is $4.43 and its two-hundred day moving average price is $5.55.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million for the quarter. On average, equities research analysts expect that Lipocine will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC increased its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.